Veri-T-001
Brief description of study
This is a phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy study of oral verdiperstat (BHV-3241) in patients with semantic variant Primary Progressive Aphasia (svPPA) due to Frontotemporal Lobar Degeneration with TDP-43 pathology (FTLD-TDP).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
